Literature DB >> 25825943

Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat.

Jean-Marc Schwarz1, Susan M Noworolski1, Michael J Wen1, Artem Dyachenko1, Jessica L Prior1, Melissa E Weinberg1, Laurie A Herraiz1, Viva W Tai1, Nathalie Bergeron1, Thomas P Bersot1, Madhu N Rao1, Morris Schambelan1, Kathleen Mulligan1.   

Abstract

CONTEXT: Consumption of high-fructose diets promotes hepatic fatty acid synthesis (de novo lipogenesis [DNL]) and an atherogenic lipid profile. It is unclear whether these effects occur independent of positive energy balance and weight gain.
OBJECTIVES: We compared the effects of a high-fructose, (25% of energy content) weight-maintaining diet to those of an isocaloric diet with the same macronutrient distribution but in which complex carbohydrate (CCHO) was substituted for fructose. DESIGN, SETTING, AND PARTICIPANTS: Eight healthy men were studied as inpatients for consecutive 9-day periods. Stable isotope tracers were used to measure fractional hepatic DNL and endogenous glucose production (EGP) and its suppression during a euglycemic-hyperinsulinemic clamp. Liver fat was measured by magnetic resonance spectroscopy.
RESULTS: Weight remained stable. Regardless of the order in which the diets were fed, the high-fructose diet was associated with both higher DNL (average, 18.6 ± 1.4% vs 11.0 ± 1.4% for CCHO; P = .001) and higher liver fat (median, +137% of CCHO; P = .016) in all participants. Fasting EGP and insulin-mediated glucose disposal did not differ significantly, but EGP during hyperinsulinemia was greater (0.60 ± 0.07 vs 0.46 ± 0.06 mg/kg/min; P = .013) with the high-fructose diet, suggesting blunted suppression of EGP.
CONCLUSION: Short-term high-fructose intake was associated with increased DNL and liver fat in healthy men fed weight-maintaining diets.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25825943      PMCID: PMC4454806          DOI: 10.1210/jc.2014-3678

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  39 in total

Review 1.  Mass isotopomer distribution analysis at eight years: theoretical, analytic, and experimental considerations.

Authors:  M K Hellerstein; R A Neese
Journal:  Am J Physiol       Date:  1999-06

2.  Respiratory motion-corrected proton magnetic resonance spectroscopy of the liver.

Authors:  Susan M Noworolski; Phyllis C Tien; Raphael Merriman; Daniel B Vigneron; Aliya Qayyum
Journal:  Magn Reson Imaging       Date:  2008-11-06       Impact factor: 2.546

Review 3.  Metabolic effects of fructose and the worldwide increase in obesity.

Authors:  Luc Tappy; Kim-Anne Lê
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

Review 4.  Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?

Authors:  G Targher; F Marra; G Marchesini
Journal:  Diabetologia       Date:  2008-09-02       Impact factor: 10.122

5.  Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans.

Authors:  Kimber L Stanhope; Jean Marc Schwarz; Nancy L Keim; Steven C Griffen; Andrew A Bremer; James L Graham; Bonnie Hatcher; Chad L Cox; Artem Dyachenko; Wei Zhang; John P McGahan; Anthony Seibert; Ronald M Krauss; Sally Chiu; Ernst J Schaefer; Masumi Ai; Seiko Otokozawa; Katsuyuki Nakajima; Takamitsu Nakano; Carine Beysen; Marc K Hellerstein; Lars Berglund; Peter J Havel
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

6.  Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association.

Authors:  Rachel K Johnson; Lawrence J Appel; Michael Brands; Barbara V Howard; Michael Lefevre; Robert H Lustig; Frank Sacks; Lyn M Steffen; Judith Wylie-Rosett
Journal:  Circulation       Date:  2009-08-24       Impact factor: 29.690

7.  Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes.

Authors:  Kim-Anne Lê; Michael Ith; Roland Kreis; David Faeh; Murielle Bortolotti; Christel Tran; Chris Boesch; Luc Tappy
Journal:  Am J Clin Nutr       Date:  2009-04-29       Impact factor: 7.045

8.  National estimates of dietary fructose intake increased from 1977 to 2004 in the United States.

Authors:  Bernadette P Marriott; Nancy Cole; Ellen Lee
Journal:  J Nutr       Date:  2009-04-29       Impact factor: 4.798

Review 9.  Triglycerides as vascular risk factors: new epidemiologic insights.

Authors:  William B Kannel; Ramachandran S Vasan
Journal:  Curr Opin Cardiol       Date:  2009-07       Impact factor: 2.161

10.  Mechanisms for the acute effect of fructose on postprandial lipemia.

Authors:  Mary F-F Chong; Barbara A Fielding; Keith N Frayn
Journal:  Am J Clin Nutr       Date:  2007-06       Impact factor: 7.045

View more
  78 in total

1.  No differential effect of beverages sweetened with fructose, high-fructose corn syrup, or glucose on systemic or adipose tissue inflammation in normal-weight to obese adults: a randomized controlled trial.

Authors:  Jessica N Kuzma; Gail Cromer; Derek K Hagman; Kara L Breymeyer; Christian L Roth; Karen E Foster-Schubert; Sarah E Holte; David S Weigle; Mario Kratz
Journal:  Am J Clin Nutr       Date:  2016-06-29       Impact factor: 7.045

Review 2.  Obesity Energetics: Body Weight Regulation and the Effects of Diet Composition.

Authors:  Kevin D Hall; Juen Guo
Journal:  Gastroenterology       Date:  2017-02-11       Impact factor: 22.682

Review 3.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

Authors:  Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson
Journal:  J Hepatol       Date:  2018-02-02       Impact factor: 25.083

Review 4.  Formation of Fructose-Mediated Advanced Glycation End Products and Their Roles in Metabolic and Inflammatory Diseases.

Authors:  Alejandro Gugliucci
Journal:  Adv Nutr       Date:  2017-01-17       Impact factor: 8.701

Review 5.  Effects of dietary macronutrients on liver fat content in adults: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Esther Winters-van Eekelen; Inge Verkouter; Harry P F Peters; Marjan Alssema; Babette G de Roos; Vera B Schrauwen-Hinderling; Kay H M Roumans; Jan W Schoones; Peter L Zock; Patrick Schrauwen; Frits R Rosendaal; Olaf M Dekkers; Renée de Mutsert
Journal:  Eur J Clin Nutr       Date:  2020-10-22       Impact factor: 4.016

Review 6.  Fructose and hepatic insulin resistance.

Authors:  Samir Softic; Kimber L Stanhope; Jeremie Boucher; Senad Divanovic; Miguel A Lanaspa; Richard J Johnson; C Ronald Kahn
Journal:  Crit Rev Clin Lab Sci       Date:  2020-01-14       Impact factor: 6.250

7.  Repurposing matrine for the treatment of hepatosteatosis and associated disorders in glucose homeostasis in mice.

Authors:  Ali Mahzari; Xiao-Yi Zeng; Xiu Zhou; Songpei Li; Jun Xu; Wen Tan; Ross Vlahos; Stephen Robinson; Ji-Ming Ye
Journal:  Acta Pharmacol Sin       Date:  2018-07-06       Impact factor: 6.150

Review 8.  Use and Importance of Nonhuman Primates in Metabolic Disease Research: Current State of the Field.

Authors:  Peter J Havel; Paul Kievit; Anthony G Comuzzie; Andrew A Bremer
Journal:  ILAR J       Date:  2017-12-01

9.  ChREBP regulates fructose-induced glucose production independently of insulin signaling.

Authors:  Mi-Sung Kim; Sarah A Krawczyk; Ludivine Doridot; Alan J Fowler; Jennifer X Wang; Sunia A Trauger; Hye-Lim Noh; Hee Joon Kang; John K Meissen; Matthew Blatnik; Jason K Kim; Michelle Lai; Mark A Herman
Journal:  J Clin Invest       Date:  2016-09-26       Impact factor: 14.808

Review 10.  Regulation of Glucose Production in the Pathogenesis of Type 2 Diabetes.

Authors:  Ashot Sargsyan; Mark A Herman
Journal:  Curr Diab Rep       Date:  2019-08-03       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.